270 related articles for article (PubMed ID: 21485696)
1. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
[TBL] [Abstract][Full Text] [Related]
2. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
3. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
4. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
5. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
6. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2D6 polymorphism and drug utilization in patients with oral lichen planus.
Paulusová V; Rösch C; Drízhal I; Perlík F; Masín V; Sukumar S; Slezák R; Slanar O
Acta Odontol Scand; 2010 Jul; 68(4):193-8. PubMed ID: 20201714
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
11. Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A
Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
15. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
19. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
20. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
